Paul Hammerness MD

Paul Hammerness, MD

Director (Medical), Outpatient Psychiatry Service

Assistant Professor of Psychiatry, Harvard Medical School

    Contact: 617-355-6680
  • Fax: 617-730-0319

Medical Services

Specialties

  • Psychopharmacology

Departments

  • Psychiatry

Programs

  • Outpatient Psychiatry
To schedule an appointment: Call 617-355-6680 or Request an Appointment

Experience and Education

Education

Medical School

Dartmouth Medical School, 1998

Hanover, NH

Internship

Mt. Auburn Hospital, 1998-1999

Cambridge, MA

Residency

Massachusetts General and McLean Hospitals, 1999-2001

Boston, MA

Fellowship

Massachusetts General and McLean Hospitals, 2001-2003

Boston, MA

Certifications

  • Child and Adolescent Psychiatry

Publications

Publications powered by Harvard Catalyst Profiles
  1. Chan E, Fogler JM, Hammerness PG. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. JAMA. 2016 May 10; 315(18):1997-2008.
  2. Hammerness PG, Karampahtsis C, Babalola R, Alexander ME. Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opin Drug Saf. 2015 Apr; 14(4):543-51.
  3. Munshi K, Alexander ME, Hammerness P. Corrected QT interval changes with atypical antipsychotics. J Am Acad Child Adolesc Psychiatry. 2015 Jan; 54(1):9-10.
  4. Ulbricht C, Basch E, Cheung L, Goldberg H, Hammerness P, Isaac R, Khalsa KP, Romm A, Rychlik I, Varghese M, Weissner W, Windsor RC, Wortley J. An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the Natural Standard Research Collaboration. J Diet Suppl. 2014 Mar; 11(1):80-120.
  5. Hammerness P, Fried R, Petty C, Meller B, Biederman J. Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD. Child Neuropsychol. 2014; 20(3):319-27.
  6. Biederman J, Pettye CR, Hammerness P, Woodworth KY, Faraon SV. Examining the nature of the association between attention-deficit hyperactivity disorder and nicotine dependence: a familial risk analysis. Can J Psychiatry. 2013 Mar; 58(3):177-83.
  7. Surman CB, Hammerness PG, Pion K, Faraone SV. Do stimulants improve functioning in adults with ADHD? A review of the literature. Eur Neuropsychopharmacol. 2013 Jun; 23(6):528-33.
  8. Ulbricht C, Basch E, Chao W, Conquer J, Costa D, Culwell S, Flanagan K, Guilford J, Hammerness P, Hashmi S, Isaac R, Rusie E, Serrano JM, Ulbricht C, Vora M, Windsor RC, Woloszyn M, Zhou S. An evidence-based systematic review of vitamin A by the natural standard research collaboration. J Diet Suppl. 2012 Dec; 9(4):299-416.
  9. Hammerness P, Joshi G, Doyle R, Georgiopoulos A, Geller D, Spencer T, Petty CR, Faraone SV, Biederman J. Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate. J Pediatr. 2013 Jan; 162(1):22-7.e2.
  10. Biederman J, Petty CR, Hammerness P, Batchelder H, Faraone SV. Cigarette smoking as a risk factor for other substance misuse: 10-year study of individuals with and without attention-deficit hyperactivity disorder. Br J Psychiatry. 2012 Sep; 201(3):207-14.
  11. Show all
  12. Fried R, Surman C, Hammerness P, Petty C, Faraone S, Hyder L, Westerberg D, Small J, Corkum L, Claudat K, Biederman J. A controlled study of a simulated workplace laboratory for adults with attention deficit hyperactivity disorder. Psychiatry Res. 2012 Dec 30; 200(2-3):949-56.
  13. Hammerness P, Zusman R, Systrom D, Surman C, Baggish A, Schillinger M, Shelley-Abrahamson R, Wilens TE. A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. World J Biol Psychiatry. 2013 May; 14(4):299-306.
  14. Adler LA, Shaw DM, Spencer TJ, Newcorn JH, Hammerness P, Sitt DJ, Minerly C, Davidow JV, Faraone SV. Preliminary examination of the reliability and concurrent validity of the attention-deficit/hyperactivity disorder self-report scale v1.1 symptom checklist to rate symptoms of attention-deficit/hyperactivity disorder in adolescents. J Child Adolesc Psychopharmacol. 2012 Jun; 22(3):238-44.
  15. Biederman J, Fried R, Hammerness P, Surman C, Mehler B, Petty CR, Faraone SV, Miller C, Bourgeois M, Meller B, Godfrey KM, Baer L, Reimer B. The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the Manchester driving behavior questionnaire. J Adolesc Health. 2012 Dec; 51(6):601-7.
  16. Surman CB, Hammerness PG, Petty C, Spencer T, Doyle R, Napolean S, Chu N, Yorks D, Biederman J. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J Biol Psychiatry. 2013 May; 14(4):291-8.
  17. Biederman J, Fried R, Hammerness P, Surman C, Mehler B, Petty CR, Faraone SV, Miller C, Bourgeois M, Meller B, Godfrey KM, Reimer B. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J Psychiatr Res. 2012 Apr; 46(4):484-91.
  18. Wozniak J, Gönenç A, Biederman J, Moore C, Joshi G, Georgiopoulos A, Hammerness P, McKillop H, Lukas SE, Henin A. A magnetic resonance spectroscopy study of the anterior cingulate cortex in youth with emotional dysregulation. Isr J Psychiatry Relat Sci. 2012; 49(1):62-9.
  19. Joshi G, Petty C, Wozniak J, Faraone SV, Doyle R, Georgiopoulos A, Hammerness P, Walls S, Glaeser B, Brethel K, Yorks D, Biederman J. A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. J Affect Disord. 2012 Feb; 136(3):1143-53.
  20. Hammerness PG, Surman CB, Chilton A. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications. Curr Psychiatry Rep. 2011 Oct; 13(5):357-63.
  21. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011 Oct; 50(10):978-90.
  22. Ulbricht C, Abrams TR, Basch E, Davies-Heerema T, Foppa I, Hammerness P, Rusie E, Tanguay-Colucci S, Taylor S, Ulbricht C, Varghese M, Weissner W, Woods J. An evidence-based systematic review of gymnema (Gymnema sylvestre R. Br.) by the Natural Standard Research Collaboration. J Diet Suppl. 2011 Sep; 8(3):311-30.
  23. Joshi G, Biederman J, Wozniak J, Doyle R, Hammerness P, Galdo M, Sullivan N, Williams C, Brethel K, Woodworth KY, Mick E. Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder. CNS Neurosci Ther. 2012 Jan; 18(1):28-33.
  24. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, Spencer T. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2010 Oct; 30(5):549-53.
  25. Spencer TJ, Mick E, Surman CB, Hammerness P, Doyle R, Aleardi M, Kotarski M, Williams CG, Biederman J. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord. 2011 May; 15(4):286-94.
  26. Wilens TE, Hammerness P, Martelon M, Brodziak K, Utzinger L, Wong P. A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010 May; 71(5):548-56.
  27. Biederman J, Joshi G, Mick E, Doyle R, Georgiopoulos A, Hammerness P, Kotarski M, Williams C, Wozniak J. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther. 2010 Apr; 16(2):91-102.
  28. Joshi G, Wozniak J, Mick E, Doyle R, Hammerness P, Georgiopoulos A, Kotarski M, Aleardi M, Williams C, Walls S, Biederman J. A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. J Child Adolesc Psychopharmacol. 2010 Feb; 20(1):7-14.
  29. Surman C, Hammerness P, Petty C, Doyle R, Chu N, Gebhard N, Williams C, Biederman J. Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study. CNS Neurosci Ther. 2010; 16(1):6-12.
  30. Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, Martelon M, Brodziak K. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):485-92.
  31. Hammerness P, Geller D, Petty C, Lamb A, Bristol E, Biederman J. Does ADHD moderate the manifestation of anxiety disorders in children? Eur Child Adolesc Psychiatry. 2010 Feb; 19(2):107-12.
  32. Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr. 2009 Jul; 155(1):84-9, 89.e1.
  33. Hammerness P, Doyle R, Kotarski M, Georgiopoulos A, Joshi G, Zeitlin S, Biederman J. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study. Eur Child Adolesc Psychiatry. 2009 Aug; 18(8):493-8.
  34. Ulbricht C, Weissner W, Hashmi S, Rae Abrams T, Dacey C, Giese N, Hammerness P, Hackman DA, Kim J, Nealon A, Voloshin R. Essiac: systematic review by the natural standard research collaboration. J Soc Integr Oncol. 2009; 7(2):73-80.
  35. Ulbricht C, Weissner W, Basch E, Giese N, Hammerness P, Rusie-Seamon E, Varghese M, Woods J. Maitake mushroom (Grifola frondosa): systematic review by the natural standard research collaboration. J Soc Integr Oncol. 2009; 7(2):66-72.
  36. Hammerness P, Surman C, Miller K. Update on adult attention-deficit/hyperactivity disorder. Curr Neurol Neurosci Rep. 2008 Nov; 8(6):484-9.
  37. Monuteaux MC, Faraone SV, Hammerness P, Wilens TE, Fraire M, Biederman J. The familial association between cigarette smoking and ADHD: a study of clinically referred girls with and without ADHD, and their families. Nicotine Tob Res. 2008 Oct; 10(10):1549-58.
  38. Hammerness PG, Wilens TE, Berul CI, Elkort MS. Supraventricular tachycardia in an adolescent with attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):219-20.
  39. Biederman J, Hammerness P, Doyle R, Joshi G, Aleardi M, Mick E. Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Neuropsychiatr Dis Treat. 2008 Feb; 4(1):203-7.
  40. Biederman J, Makris N, Valera EM, Monuteaux MC, Goldstein JM, Buka S, Boriel DL, Bandyopadhyay S, Kennedy DN, Caviness VS, Bush G, Aleardi M, Hammerness P, Faraone SV, Seidman LJ. Towards further understanding of the co-morbidity between attention deficit hyperactivity disorder and bipolar disorder: a MRI study of brain volumes. Psychol Med. 2008 Jul; 38(7):1045-56.
  41. Biederman J, Mick EO, Surman C, Doyle R, Hammerness P, Michel E, Martin J, Spencer TJ. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2007 Sep 14; 7:49.
  42. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, Kotarski M, Aleardi M, Wozniak J. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr. 2007 Sep; 12(9):683-9.
  43. Harpold T, Biederman J, Gignac M, Hammerness P, Surman C, Potter A, Mick E. Is oppositional defiant disorder a meaningful diagnosis in adults? Results from a large sample of adults with ADHD. J Nerv Ment Dis. 2007 Jul; 195(7):601-5.
  44. Hammerness P, Harpold T, Petty C, Menard C, Zar-Kessler C, Biederman J. Characterizing non-OCD anxiety disorders in psychiatrically referred children and adolescents. J Affect Disord. 2008 Jan; 105(1-3):213-9.
  45. Ulbricht C, Armstrong J, Basch E, Basch S, Bent S, Dacey C, Dalton S, Foppa I, Giese N, Hammerness P, Kirkwood C, Sollars D, Tanguay-Colucci S, Weissner W. An evidence-based systematic review of Aloe vera by the natural standard research collaboration. J Herb Pharmacother. 2007; 7(3-4):279-323.
  46. Ulbricht C, Basch E, Burke D, Cheung L, Ernst E, Giese N, Foppa I, Hammerness P, Hashmi S, Kuo G, Miranda M, Mukherjee S, Smith M, Sollars D, Tanguay-Colucci S, Vijayan N, Weissner W. Fenugreek (Trigonella foenum-graecum L. Leguminosae): an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother. 2007; 7(3-4):143-77.
  47. Basch E, Bent S, Collins J, Dacey C, Hammerness P, Harrison M, Smith M, Szapary P, Ulbricht C, Vora M, Weissner W. Flax and flaxseed oil (Linum usitatissimum): a review by the Natural Standard Research Collaboration. J Soc Integr Oncol. 2007; 5(3):92-105.
  48. Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M, Dougherty M, Harpold T, Hammerness P, Randall E, Lyoo IK, Renshaw PF. Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. J Affect Disord. 2007 Apr; 99(1-3):19-25.
  49. Biederman J, Mick E, Spencer T, Surman C, Hammerness P, Doyle R, Dougherty M, Aleardi M, Schweitzer K. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr. 2006 May; 11(5):390-6.
  50. Wilens TE, Zusman RM, Hammerness PG, Podolski A, Whitley J, Spencer TJ, Gignac M, Biederman J. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. J Clin Psychiatry. 2006 May; 67(5):696-702.
  51. Biederman J, Mick E, Faraone S, Hammerness P, Surman C, Harpold T, Dougherty M, Aleardi M, Spencer T. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2006 Apr; 26(2):163-6.
  52. Hammerness PG, Vivas FM, Geller DA. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatr. 2006 Feb; 148(2):158-65.
  53. Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M, Dougherty M, Harpold T, Hammerness P, Randall E, Renshaw PF. Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. Am J Psychiatry. 2006 Feb; 163(2):316-8.
  54. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006 May 1; 59(9):829-35.
  55. Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, Kroll D, Garraway L, Vora M, Woods J. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med. 2005 Dec; 13(4):279-90.
  56. Ulbricht C, Basch E, Boon H, Ernst E, Hammerness P, Sollars D, Tsourounis C, Woods J, Bent S. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf. 2005 Jul; 4(4):779-94.
  57. Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005 Feb; 66(2):253-9.
  58. Hammerness P, Monuteaux MC, Faraone SV, Gallo L, Murphy H, Biederman J. Reexamining the familial association between asthma and ADHD in girls. J Atten Disord. 2005 Feb; 8(3):136-43.
  59. Ulbricht C, Basch E, Hammerness P, Vora M, Wylie J, Woods J. An evidence-based systematic review of belladonna by the natural standard research collaboration. J Herb Pharmacother. 2004; 4(4):61-90.
  60. Basch E, Ulbricht C, Hammerness P, Bevins A, Sollars D. Thyme (Thymus vulgaris L.), thymol. J Herb Pharmacother. 2004; 4(1):49-67.
  61. Hammerness P, Basch E, Ulbricht C, Barrette EP, Foppa I, Basch S, Bent S, Boon H, Ernst E. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003 Jul-Aug; 44(4):271-82.
  62. Wilens TE, Prince JB, Spencer T, Van Patten SL, Doyle R, Girard K, Hammerness P, Goldman S, Brown S, Biederman J. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry. 2003 Jul 1; 54(1):9-16.
  63. Ulbricht C, Basch E, Ulbricht C, Sollars D, Hammerness P, Hashmi S. Wild yam (Dioscoreaceae). J Herb Pharmacother. 2003; 3(4):77-91.
  64. Ulbricht C, Basch E, Vora M, Sollars D, Rogers A, Basch S, Smith M, Moffet H, Hammerness P. Chaparral monograph:a clinical decision support tool. J Herb Pharmacother. 2003; 3(1):121-33.
  65. Basch E, Ulbricht C, Hammerness P, Vora M. Marshmallow (Althaea officinalis L.) monograph. J Herb Pharmacother. 2003; 3(3):71-81.
  66. Hammerness P, Parada H, Abrams A. Linezolid: MAOI activity and potential drug interactions. Psychosomatics. 2002 May-Jun; 43(3):248-9.
  67. Hammerness P, Ulbricht C, Barrette EP, Boon H, Szapary P, Sollars D, Smith M, Tsourounis C, Bent S, Basch E. Shark cartilage monograph: a clinical decision support tool. J Herb Pharmacother. 2002; 2(2):71-93.
  68. Basch E, Ulbricht C, Hammerness P, Tsouronis C, Sollars D, Rogers A, Basch S, Bent S, Boon H, Ernst E. Kava monograph: a clinical decision support tool. J Herb Pharmacother. 2002; 2(4):65-91.
  69. Nugent WC, Edney MT, Hammerness PG, Dain BJ, Maurer LH, Rigas JR. Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann Thorac Surg. 1997 Jan; 63(1):193-7.
  70. Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994 May; 55(5):200-5.
  71. Lafer B, Fava M, Hammerness P, Rosenbaum JF. The influence of DST and TRH test administration on depression assessments: a controlled study. Biol Psychiatry. 1993 Nov 1; 34(9):650-3.
  72. Pollack MH, Hammerness P. Adjunctive yohimbine for treatment in refractory depression. Biol Psychiatry. 1993 Feb 1; 33(3):220-1.
  73. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med. 1992; 22(4):305-27.
  74. Hammerness P, Biederman J, Petty C, Henin A, Moore CM. Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: a controlled pilot study. CNS Neurosci Ther. 2012 Jan; 18(1):34-40.
  75. Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatr Dis Treat. 2009; 5:215-26.
  76. Ulbricht C, Basch E, Bent S, Boon H, Corrado M, Foppa I, Hashmi S, Hammerness P, Kingsbury E, Smith M, Szapary P, Vora M, Weissner W. Evidence-based systematic review of saw palmetto by the Natural Standard Research Collaboration. J Soc Integr Oncol. 2006; 4(4):170-86.
  77. Hammerness P, Georgiopoulos A, Doyle RL, Utzinger L, Schillinger M, Martelon M, Brodziak K, Biederman J, Wilens TE. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):493-9.
  78. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005 Oct 1; 58(7):589-94.
To schedule an appointment: Call 617-355-6680 or Request an Appointment

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close